STAT5B: Associations with Leukemia

Baoqi He

Baoqi He
Dec 12, 2022 12:40:03 PM

What is STAT5B?


STAT5B belongs to the STAT (signal transducer and activator of transcription) protein family, a group of latent cytosolic transcription factors activated by Janus kinase (JAK) tyrosine kinases. The JAK-STAT signaling pathway is responsible for many important biological processes including cell proliferation, differentiation, apoptosis, and is also involved in the modulation of a variety of cytokines to control the immune response. 


ABclonal JAK STAT signaling pathway


Previous studies have shown that STAT5B is involved in T cell receptor-mediated signaling, adult mammary gland development, and sexual dimorphism of liver gene expression. When activated, STAT5B interacts with the activated receptor through its Src-homology 2 (SH2) domain, and is subsequently phosphorylated by JAK. Subsequently, STAT5B homodimers and STAT5A/STAT5B heterodimers can translocate to the nucleus to regulate gene transcription through its DNA-binding domain recognizing specific sequences, including the interferon gamma (IFN-γ) activation sequence. 1


STAT5B in Leukemia


cancerCancer can occur in many different types of cells and tissues in the human body, that that includes the white blood cells. Large granular lymphocytic leukemia (LGL) and acute promyelocytic leukemia (APL) are blood-borne cancers that result from abnormalities in STAT5B-mediated signaling. 2, 3 APL, in particular, involves an abnormal accumulation of immature granulocytes called promyelocytes. APL is characterized by a chromosomal translocation involving the retinoic acid receptor alpha (RARA) gene, which in many cases is fused with the STAT5B gene and thought to be the causative mutation for this type of cancer. 3 There is potential to target STAT5B as a therapeutic strategy against leukemia. 2, 3


How ABclonal Can Help


As an original manufacturer, ABclonal uses proven methodologies to produce consistently high-quality antibodies against your desired targets, including STAT5B. Our STAT5B rabbit monoclonal antibody is validated with knockout cell lines to demonstrate specificity, and has been corroborated by independent characterization. Feel free to contact us at or visit our website to explore our vast catalog of antibody reagents to accelerate your research!

Knockout validation of STAT5B antibody



  1. T Kanai, J Jenks & KC Nadeau (2012) "The STAT5b pathway defect and autoimmunity." Front Immunol 3:00234 (Epub)
  2. HLM Rajala & S Mustjoki (2013) "STAT5b in LGL leukemia - a novel therapeutic target?" Oncotarget 4(6):808-809.
  3. L Wang, X Yan & J He (2020) "Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?" Medicine (Baltimore) 99(43):e22923 (Epub).
  4. Ayoubi et al. (2022) "Antibody Characterization Report for Signal transducer and activator of transcription 5B (STAT5B)" Accessible via Zenodo.


Tags: ABclonal News, ABclonal Technology, cancer therapy, therapeutics, targeted therapy, STAT5B, leukemia, large granular lymphocytic leukemia, acute promyelocytic leukemia, LGL, APL, JAK STAT, APML, AML

Baoqi He

Baoqi He

Baoqi is a biological tech support intern at ABClonal. She is a current junior at Davidson College majoring in biology. Baoqi likes exploring various topics related to biology, such as immunology and genetics. She enjoys dancing and reading novels in her spare time.